Gene · 599
Papers4,142
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 4,142
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia. | Leukemia | 2024 | 37945692 | PubTator, text mining | PubMed |
| MiR-150-5p contributes to unexplained recurrent spontaneous abortion by targeting VEGFA and downregulating the PI3K/AKT/mTOR signaling pathway. | J Assist Reprod Genet | 2024 | 37921969 | PubTator, text mining | PubMed |
| ATP1A1/BCL2L1 predicts the response of myelomonocytic and monocytic acute myeloid leukemia to cardiac glycosides. | Leukemia | 2024 | 37904054 | PubTator, text mining | PubMed |
| Association between serum vitamin D status and uterine leiomyomas: a case-control study. | Obstet Gynecol Sci | 2024 | 37848168 | PubTator, text mining | PubMed |
| CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia is sensitive to BCL-XL inhibition by navitoclax and DT2216. | Blood Adv | 2024 | 37729615 | PubTator, text mining | PubMed |
| Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax. | Haematologica | 2024 | 37534528 | PubTator, text mining | PubMed |
| Screening of natural product libraries in MCF7 cell line reveals the pro-apoptotic properties of β tetralone. | J Biomol Struct Dyn | 2024 | 37014028 | PubTator, text mining | PubMed |
| Targeting BCL2 pathways in CLL: a story of resistance and ingenuity. | Cancer Drug Resist | 2023 | 38263980 | PubTator, text mining | PubMed |
| Maximizing Anticancer Response with MPS1 and CENPE Inhibition Alongside Apoptosis Induction. | Pharmaceutics | 2023 | 38258067 | PubTator, text mining | PubMed |
| Prediction of Chemoresistance-How Preclinical Data Could Help to Modify Therapeutic Strategy in High-Grade Serous Ovarian Cancer. | Curr Oncol | 2023 | 38248100 | PubTator, text mining | PubMed |
| Fraisinib: a calixpyrrole derivative reducing A549 cell-derived NSCLC tumor in vivo acts as a ligand of the glycine-tRNA synthase, a new molecular target in oncology. | Front Pharmacol | 2023 | 38235113 | PubTator, text mining | PubMed |
| Venetoclax and Hypomethylating Agent Combination in Myeloid Malignancies: Mechanisms of Synergy and Challenges of Resistance. | Int J Mol Sci | 2023 | 38203655 | PubTator, text mining | PubMed |
| Serum Calretinin and Genetic Variability as a Prognostic and Predictive Factor in Malignant Mesothelioma. | Int J Mol Sci | 2023 | 38203360 | PubTator, text mining | PubMed |
| Oxidative Stress Mediates Epigenetic Modifications and the Expression of miRNAs and Genes Related to Apoptosis in Diabetic Retinopathy Patients. | J Clin Med | 2023 | 38202081 | PubTator, text mining | PubMed |
| Association between Genetic Polymorphism of The lncRNA MIAT rs1894720 with Ischemic Stroke Risk and lncRNA MIAT Expression Levels in The Blood after An Ischemic Stroke: A Case-Control Study. | Cell J | 2023 | 38192257 | PubTator, text mining | PubMed |
| Advances in the role of microRNAs associated with the PI3K/AKT signaling pathway in lung cancer. | Front Oncol | 2023 | 38169723 | PubTator, text mining | PubMed |
| Oncoviruses: Induction of cancer development and metastasis by increasing anoikis resistance. | Heliyon | 2023 | 38144298 | PubTator, text mining | PubMed |
| Herbal Melanin Inhibits Real-Time Cell Proliferation, Downregulates Anti-Apoptotic Proteins and Upregulates Pro-Apoptotic p53 Expression in MDA-MB-231 and HCT-116 Cancer Cell Lines. | Medicina (Kaunas) | 2023 | 38138165 | PubTator, text mining | PubMed |
| The Role of t(11;14) in Tailoring Treatment Decisions in Multiple Myeloma. | Cancers (Basel) | 2023 | 38136374 | PubTator, text mining | PubMed |
| Genome-wide CRISPR/Cas9 screening for drug resistance in tumors. | Front Pharmacol | 2023 | 38084101 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/599/papers?page=6